Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) ended Wednesday session in red amid volatile trading. The shares closed down -0.12 points or -2.28% at $5.14 with 1.92 million shares getting traded. Post opening the session at $5.25, the shares hit an intraday low of $5.12 and an intraday high of $5.32 and the price vacillated in this range throughout the day. The company has a market cap of $885.33 million and the numbers of outstanding shares have been calculated to be 179.45 million shares.
Synergy Pharmaceuticals Inc (SGYP) announced that the independent Compensation Committee of the Board of Directors of Synergy approved the grant of an inducement stock option to purchase 50,000 shares of Synergy common stock to one new employee, with a grant date of September 19, 2016 (the “Q3 2016 Inducement Grant”).
The Q3 2016 Inducement Grant has an exercise price per share equal to the closing price of the Company’s common stock on September 19, 2016, the date of grant. The stock option has a 10 year term and vests in equal amounts on the anniversary of the date of grant over three years, subject to the new employee’s continued service with the Company through the respective vesting dates. The stock option was granted as an inducement equity award outside of the Company’s 20008 Equity Compensation Incentive Plan, as amended, and was made as an inducement material to such employee’s acceptance of employment with the Company.
Shares of Hologic, Inc. (NASDAQ:HOLX) ended Wednesday session in green amid volatile trading. The shares closed up +0.12 points or 0.31% at $38.81 with 1.37 million shares getting traded. Post opening the session at $38.84, the shares hit an intraday low of $38.53 and an intraday high of $38.99 and the price vacillated in this range throughout the day. The company has a market cap of $10.40 billion and the numbers of outstanding shares have been calculated to be 277.42 million shares.
Hologic Inc. (HOLX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company’s Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).
Hologic’s Zika virus assay was authorized for emergency use with serum and plasma (blood) samples in June 2016. Its new use with urine samples lengthens the time period during which patients can be tested for Zika from seven days to 14 days following symptoms, as recommended by the U.S. Centers for Disease Control and Prevention (CDC).
“This action by FDA is significant because it gives many more people the opportunity to be tested with our highly sensitive assay,” said Tom West, Division President of Diagnostic Solutions at Hologic. “In particular, this expanded indication allows us to better serve public health labs, increasing access to more people to detect and diagnose more disease.”